THE CLINICAL AND LABORATORY EFFECTIVENESS OF OSELTAMIVIR FOR TREATMENT OF INFLUENZA IN HOSPITALIZED PATIENTS

Cover Page

Cite item

Abstract

The goal of our study was to estimate the efficacy of antiviral drug Oseltamivir for influenza treatment. We assessed the effect of Oseltamivir on the immune status of the 75 patients. It was formed 2 groups of observations with confirmed diagnosis of influenza: 38 received therapy Oseltamivir and 37 people receiving pathogenetic treatment. Treatment Oseltamivir contributes to a significant reduction in the duration of the catarrhal and intoxication syndromes and prevents the development of complications and exacerbations of chronic disease in persons with modified backdrop premorbid, which indicates for its high antiviral activity. We can assume the effect of Oseltamivir for restore the disturbed balance of cytokines, on assessing the dynamics of IL-1β, IL-8, IFNα, IFNγ in the serum.

About the authors

L. V. Voloschcuk

Research Institute of Influenza Ministry of Healthcare of the Russian Federation

Author for correspondence.
Email: 7970747@mail.ru
PhD (Medicine), Senior Researcher, Division of Viral Respiratory Infections in Adults, 197376, Russian Federation, St. Petersburg, Professor Popov str., 15/17 Russian Federation

E. G. Golovacheva

Research Institute of Influenza Ministry of Healthcare of the Russian Federation

Email: fake@neicon.ru
PhD (Medicine), Senior Researcher, Division of Viral Respiratory Infections in Children, 197376, Russian Federation, St. Petersburg, Professor Popov str., 15/17 Russian Federation

A. A. Go

Research Institute of Influenza Ministry of Healthcare of the Russian Federation

Email: fake@neicon.ru
Chief, Division of Viral Respiratory Infections in Adults, 197376, Russian Federation, St. Petersburg, Professor Popov str., 15/17 Russian Federation

A. L. Mushkatina

Research Institute of Influenza Ministry of Healthcare of the Russian Federation

Email: fake@neicon.ru
Researcher, Division of Viral Respiratory Infections in Adults, 197376, Russian Federation, St. Petersburg, Professor Popov str., 15/17 Russian Federation

P. V. Zarishnuk

Research Institute of Influenza Ministry of Healthcare of the Russian Federation

Email: fake@neicon.ru
Senior Researcher, Division of Viral Respiratory Infections in Adults, 197376, Russian Federation, St. Petersburg, Professor Popov str., 15/17 Russian Federation

G. L. Dnieprovskay

Research Institute of Influenza Ministry of Healthcare of the Russian Federation

Email: fake@neicon.ru
Leading Researcher Division of Viral Respiratory Infections in Adults Ministry of Health Development of the Russian Federation Research Institute of Influenza, 197376, Russian Federation, St. Petersburg, Professor Popov str., 15/17 Russian Federation

T. L. Tumina

Research Institute of Influenza Ministry of Healthcare of the Russian Federation

Email: fake@neicon.ru
Researcher, Division of Viral Respiratory Infections in Adults, 197376, Russian Federation, St. Petersburg, Professor Popov str., 15/17 Russian Federation

References

  1. Беляева Т.В., Исаков В.А., Рахманова А.Г., Тимченко В.И., Каболова И.В., Яковлев А.А. Грипп А (Н1N1) Калифорния («свиной грипп»). Клиника, диагностика, этиология: Методические рекомендации для врачей. СПб., 2009. 87 с. [Belyaeva T.V., Isakov V.A., Rakhmanova A.G., Timchenko V.I., Kabolova I.V., Yakovlev A.A. Gripp A (N1N1) Kaliforniya («svinoi gripp»). Klinika, diagnostika, etiologiya: Metodicheskie rekomendatsii dlya vrachei [Influenza A (H1N1) California («swine flu»). Clinic, diagnosis, etiology: Methodical recommendations for doctors]. St. Petersburg, 2009, 87 p.]
  2. Еженедельный бюллетень по информированному мониторингу проявлений гриппа H1N1 и других генотипов вируса с пандемическим потенциалом за период 09.05.2010–16.06.2010 // Референс-лаборатория ВОЗ по диагностике гриппа Н5 ФГУН ГНЦВБ. Выпуск 7. 25 с. [Ezhenedel’nyi byulleten’ po informirovannomu monitoringu proyavlenii grippa H1N1 i drugikh genotipov virusa s pandemicheskim potentsialom za period 09.05.2010–16.06.2010 [Weekly Bulletin informed monitoring of manifestations of H1N1 and other strains of the virus with pandemic potential during the period 09.05.2010–16.06.2010]. Referens-laboratoriya VOZ po diagnostike grippa H5 FGUN GNTsVB = Reference Laboratory WHO for the Diagnosis of Influenza H5 FSRI GMCVB, iss. 7, 25 p. (In Russ.)]
  3. Инфекционная заболеваемость за январь–декабрь 2008 г. в Российской Федерации // Детские инфекции. 2009. Т. 8. С. 1–3. [Infektsionnaya zabolevaemost’ za yanvar’–dekabr’ 2008 g. v Rossiiskoi Federatsii [Infectious morbidity in January–December of 2008 in the Russian Federation] Detskie infektsii = Childhood infections. 2009, vol. 8, pp. 1–3. (In Russ.)]
  4. Сведения об инфекционных и паразитарных заболеваниях за январь–декабрь 2010. Российская Федерация // Детские инфекции. 2011. Т. 10. № 2. С. 3. [Information about infectious and parasitic diseases, January–December 2010. Russian Federation. Detskie infektsii = Childhood infections, 2011, vol. 10, no. 2, p. 3. (In Russ.)]
  5. Яковлев А.А., Полушин Ю.С., Котлярова С.И., Мусатов В.Б., Федуняк И.П., Цинзерлинг В.А., Вашукова С.С., Лукашевич Э.Н. Грипп A Н1N1/2009 Калифорния — reassortment of vRNAs — как медицинская проблема // Вестник Санкт-Петербургского университета. 2010. № 3. С. 45–55. [Yakovlev A.A., Polushin Y.S., Kotlyarova S.I., Musatov V.B., Feduniak I.P., Zinserling V.A., Vashukova S.S., Lukashevich E.N. Influenza A H1N1/2009 California reassortment of vRNAs as a medical problem. Vestnik Sankt-Peterburgskogo universiteta = Herald of St. Petersburg University, 2010, no. 3, pp. 45–55. (In Russ.)]
  6. Bussfeld D., Bacher M., Moritz A., Gemsa D., Sprenger H. Expression of transcription factor genes after influenza virus A infection. Immunobiology, 1997, vol. 198, pp. 291–298. doi: 10.1016/S0171-2985(97)80049-6
  7. CDC news conference with Thomas R. Frieden. Centers for Disease Control and Prevention, Dec. 10, 2009.
  8. McPhie K., Taylor J., Rashid H., Heron L., Dwyer D., Booy R. A randomized study of standard Dixit R., Khandaker G., Hay P., versus double dose oseltamivir for treating influenza in the community. Antivir. Ther., 2014, 10 p. doi: 10.3851/IMP2807
  9. Hermes-Lima M., Storey J.M., Storey K.B. Antioxidant defenses and metabolic depression. The hypothesis of preparation for oxidative stress in land snails. Comp. Biochem. Physiol. B. Biochem. Mol. Biol., 1998, vol. 120, pp. 437–448. doi: 10.1016/S0305-0491(98)10053-6
  10. Garg S., Fry A.M., Patton M., Fiore A.E., Finelli L. Antiviral treatment of influenza in children. Pediatr. Infect. Dis. J., 2012, vol. 31, iss. 2, pp. 43–51. doi: 10.1097/INF.0b013e31824671ab
  11. Louie J.K., Schechter R., Honarmand S., Guevara H.F., Shoemaker T.R., Madrigal N.Y., Woodfill C.J., Backer H.D., Glaser C.A. Severe pediatric influenza in California, 2003–2005: implications for immunization recommendation. J. Pediatr., 2006, vol. 117, pp. 610–618. doi: 10.1542/peds.2005-1373
  12. Nguyen H.T., Fry A.M., Gubareva L.V. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir. Ther., 2012, vol. 17, no. 1, pp. 159–173. doi: 10.3851/IMP2067
  13. -Pascual L., Arjona-Berral J.E., Mar Nieto ín-Martín E.M., Muñoz-Gomariz E., Ilich I., Castelo-Branco C. Early prophylactic treatment in pregnant women during the 2009–2010 H1N1 pandemic: obstetric and neonatal outcomes. J. Obstet. Gynaecol., 2013, vol. 33, no. 2, pp. 128–134. doi: 10.3109/01443615.2012.740526
  14. Ramshaw I.A., Ramsay A.J., Karupiah G., Rolph M.S., Mahalingam S., Ruby J.C. Cytokines and immunity to viral infections. Immunol. Rev., 1998, vol. 159, no. 1, pp. 69–77. doi: 10.1111/j.1600-065X.1997.tb01011.x
  15. Wong Z.X., Jones J.E., Anderson G.P., Gualano R.C. Oseltamivir treatment of mice before or after mild influenza infection reduced cellular and cytokine inflammation in the lung. Influenza Other Respir. Viruses, 2011, vol. 5, iss. 5, pp. 343–350. doi: 10.1111/j.1750-2659.2011.00235.x

Copyright (c) 2015 Voloschcuk L.V., Golovacheva E.G., Go A.A., Mushkatina A.L., Zarishnuk P.V., Dnieprovskay G.L., Tumina T.L.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies